CLGN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.374

Open

0.356

VWAP

0.36

Vol

17.85K

Mkt Cap

5.35M

Low

0.356

Amount

6.51K

EV/EBITDA(TTM)

--

Total Shares

14.42M

EV

1.09M

EV/OCF(TTM)

--

P/S(TTM)

12.18

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).

Show More

Events Timeline

(ET)

2026-04-13

07:10:00

CollPlant Terminates Development Agreement with AbbVie, Looks Ahead to 2026

2026-04-13

07:10:00

Company Plans to Cut Workforce by Approximately 50% to Optimize Costs

2026-03-30 (ET)

2026-03-30

18:00:00

CollPlant Files to Sell 3.3M Ordinary Shares

2026-03-24 (ET)

2026-03-24

16:10:00

CollPlant Receives Nasdaq Non-Compliance Notice

2026-02-26 (ET)

2026-02-26

08:20:00

CollPlant Secures Korean Patent for Photocurable Dermal Filler Technology

2026-02-05 (ET)

2026-02-05

08:10:00

CollPlant Biotechnologies Issues 1.6M Shares at $1.25 Each

2026-01-09 (ET)

2026-01-09

16:20:00

CollPlant Files $100M Mixed Securities Shelf

2025-11-26 (ET)

2025-11-26

07:35:33

CollPlant to Cut Workforce by 25%

2025-11-26

07:32:38

CollPlant announces Q3 non-GAAP EPS of 25 cents, compared to a loss of 33 cents in the previous year.

News

seekingalpha

05-29seekingalpha

CollPlant Reports Q1 Earnings Results

PRnewswire

05-29PRnewswire

CollPlant Reports Q1 2026 Financial Results and Corporate Update

Newsfilter

05-29Newsfilter

CollPlant Reports Q1 2026 Financial Results and Strategic Developments

04-13PRnewswire

CollPlant Ends AbbVie Partnership, Eyes New Opportunities Ahead

seekingalpha

03-26seekingalpha

CollPlant Biotechnologies Reports FY 2025 Financial Results

PRnewswire

03-26PRnewswire

CollPlant Reports 2025 Financial Results and Corporate Updates

Valuation Metrics

The current forward P/E ratio for Collplant Biotechnologies Ltd (CLGN.O) is 80.00, compared to its 5-year average forward P/E of 15.51. For a more detailed relative valuation and DCF analysis to assess Collplant Biotechnologies Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

15.51

Current PE

80.00

Overvalued PE

64.40

Undervalued PE

-33.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.00

Current EV/EBITDA

-0.01

Overvalued EV/EBITDA

0.01

Undervalued EV/EBITDA

-0.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

54.99

Current PS

0.70

Overvalued PS

168.35

Undervalued PS

-58.37

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Intellectia · 22 candidates

Industry: Biotechnology & Medical Research, PharmaceuticalsRegion: USCurrent Ratio: >= 1.20List Exchange: XNYS, XNAS, XASEPs Ratio: <= 4.00Year Price Change Pct: <= $-40.00

Ticker

Name

Market Cap$

Mustang Bio Inc

5.30M

Enveric Biosciences Inc

3.71M

LifeVantage Corp

53.14M

Perrigo Company PLC

1.49B

cbdMD Inc

7.14M

InMed Pharmaceuticals Inc

2.37M

setup swing trade

Intellectia · 13 candidates

Sector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical ResearchRegion: USPrice: $0.10 - $1.00Rsi Category: oversoldList Exchange: XNAS, XNYS, XASEMoving Average Relationship: PriceBelowMA20, PriceBelowMA60, PriceBelowMA200

Ticker

Name

Market Cap$

Reviva Pharmaceuticals Holdings Inc

25.77M

Aditxt Inc

898.13K

CDT Equity Inc

1.59M

Collplant Biotechnologies Ltd

7.54M

Anebulo Pharmaceuticals Inc

17.47M

Ernexa Therapeutics Inc

7.94M

Whales Holding CLGN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Collplant Biotechnologies Ltd (CLGN) stock price today?

The current price of CLGN is 0.363 USD — it has decreased -2.16

What is Collplant Biotechnologies Ltd (CLGN)'s business?

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).

What is the price predicton of CLGN Stock?

Wall Street analysts forecast CLGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLGN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Collplant Biotechnologies Ltd (CLGN)'s revenue for the last quarter?

Collplant Biotechnologies Ltd revenue for the last quarter amounts to 73.00K USD, decreased -96.45

What is Collplant Biotechnologies Ltd (CLGN)'s earnings per share (EPS) for the last quarter?

Collplant Biotechnologies Ltd. EPS for the last quarter amounts to -0.23 USD, increased 76.92

How many employees does Collplant Biotechnologies Ltd (CLGN). have?

Collplant Biotechnologies Ltd (CLGN) has 39 emplpoyees as of June 11 2026.

What is Collplant Biotechnologies Ltd (CLGN) market cap?

Today CLGN has the market capitalization of 5.35M USD.